Chemical Structure (Temodar 01)
Temodar Capsule
Product Images NDC 0085-1366
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Temodar (NDC 0085-1366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Temodar 02)
This appears to be a section of a clinical trial report presenting survival data of a population under study. The overall survival is reported as a hazard ratio (HR) with confidence interval (95% CI) and a P-value obtained using a log-rank test. The data table shows the number of subjects at risk at specific time points from the beginning of the study. However, it is unclear what the numbers in the last row represent.*
Principal Display Panel (5 mg Capsule Sachet Carton)
This is a prescription medication called Temodar (temozolomide) in capsule form, containing 5mg of the active ingredient. The recommended dose should be determined based on package instructions, and the capsules should not be opened or damaged. It is cytotoxic and should be swallowed whole, without any contact with the skin, eyes, or nose. This medication should be stored between 15-20°C (58-86°F). The package contains 5 individual sachets, each containing one capsule. The GTIN code is 0030085300034.*
Principal Display Panel (20 mg Capsule Sachet Carton)
Principal Display Panel (100 mg Capsule Sachet Carton)
This is a description of Temodar® (temozolomide) capsules. Each capsule contains 100 mg of temozolomide. The package insert should be carefully read for the recommended dose. The drug is cytotoxic, so it is not advised to open the capsule and it should be swallowed whole. If the capsule is damaged, contact with skin, eyes or nose should be avoided. The package contains 5 individual sachets, and each sachet contains one capsule. Storage temperature is between 15-30°C.*
Principal Display Panel (140 mg Capsule Sachet Carton)
Temodar (temozolomide) Capsules are used for oral administration for cytotoxic purposes. Each capsule has 140 mg temozolomide that one should swallow no matter what. The capsules must be kept entirely and should not be opened. However, if a capsule becomes damaged, make sure to avoid contact with the nose, eyes, or skin. A medical expert must be consulted before establishing a daily regimen. The package insert or recommendations must be seen before using varying capsule strengths. The available contact details are MSD Global GmbH, Vienna, Austria.*
Principal Display Panel (180 mg Capsule Sachet Carton)
Each capsule of Temodar contains 180 mg of temozolomide and it is intended for oral administration. The package should be read carefully before use as directions regarding the use of varying capsule strengths for establishing a daily regimen should be followed. The capsules are cytotoxic and should not be opened. If a capsule is damaged, avoid contact with skin, eyes, or nose. The usual dose is to be determined according to the package insert's recommendation. The capsules should be stored at controlled room temperature. The package contains five individual sachets, each containing one capsule. The product is only available with a prescription.*
Principal Display Panel (250 mg Capsule Sachet Carton)
This is a description of a medication called Temodar, containing the active ingredient Temozolomide at a strength of 250 mg per capsule. It is available as an oral capsule and is cytotoxic. The recommended dose can be found in the package insert. The medication comes in individual sachets, with each sachet containing one capsule, and it should be stored at a temperature between 5-30°C. If the capsules are damaged, avoid contact with the skin, nose, or eyes.*
Principal Display Panel (100 mg Vial Carton)
Temodar® is a medication administered intravenously primarily to treat certain types of brain tumors. The drug is only to be used with a well-established reconstitution protocol, and the vials must be stored at appropriate cool temperatures until usage. The package for Temodar® contains directions and patient information at the end of its insert. If the vial is damaged, the drug may be cytotoxic and should not be used.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
